Gan, Lee

Gan & Lee Pharmaceuticals Announces U.S. FDA Clearance of the IND application for the innovative Bi-weekly GLP-1RA GZR18 Injection, Bofanglutide, with chronic weight management Indication

Published on 08/07/2025 at 18:04 | prnewswire.co.uk

Gan & Lee Pharmaceuticals Denmark Finland Germany Netherlands Sweden United Kingdom New Jersey China Austria

(Media) 
BD@ganlee.com (Business Development)
info.medical@ganlee.com (Medical Information)

Logo - https://mma.prnewswire.com/media/2439708/Gan_Lee_Pharmaceuticals_Logo.jpg 

Cision View original content:https://www.prnewswire.co.uk/news-releases/gan--lee-pharmaceuticals-announces-us-fda-clearance-of-the-ind-application-for-the-innovative-bi-weekly-glp-1ra-gzr18-injection-bofanglutide-with-chronic-weight-management-indication-a-phase-2-head-to-head-with-tirzepatide-c-302335005.html

en | boerse | 67989058 |